A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer

The mortality rate in patients suffering from non-small cell lung cancer (NSCLC) is quite high. This type of cancer mainly occurs due to rearrangements in the anaplastic lymphoma kinase (ALK) gene which leads to form an oncogene of fused gene NPM-ALK. Brigatinib is recently approved by FDA in April...

Descripción completa

Detalles Bibliográficos
Autores principales: Bedi, Silky, Khan, Shah A., AbuKhader, Majed M., Alam, Perwez, Siddiqui, Nasir A., Husain, Asif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128722/
https://www.ncbi.nlm.nih.gov/pubmed/30202213
http://dx.doi.org/10.1016/j.jsps.2018.04.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128722/
https://www.ncbi.nlm.nih.gov/pubmed/30202213
http://dx.doi.org/10.1016/j.jsps.2018.04.010

Ejemplares similares